Sulglicotide

Summary

Sulglicotide (also known as Glypressin in some contexts, but more specifically marketed as Tepilta) is a sulfated glycopeptide extracted from porcine duodenal mucosa. It is used primarily in the treatment of peptic ulcer disease and gastritis. It acts as a gastroprotective agent rather than an acid suppressor, reinforcing the mucosal defense mechanisms.

Mechanism of Action

Sulglicotide is a sulfated glycopeptide derived from duodenal mucosa that acts as a cytoprotective agent. It enhances the gastric mucosal barrier by stimulating mucus secretion, promoting prostaglandin synthesis, and inhibiting pepsin activity, thereby protecting the gastric epithelium from acid-induced damage.

Routes of Administration

Goals & Uses

• Mucosal cytoprotectionGastrointestinalModerate
• Pepsin inhibitionEnzyme InhibitionLow
• Gastritis managementGastrointestinalModerate
• Peptic ulcer treatmentGastrointestinalModerate

Contraindications

• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• Hypersensitivity to porcine-derived productsAllergy / ImmunologicalHigh

Adverse Effects

• Allergic reactionImmunologicRareImmune-mediated hypersensitivity response
• Abdominal discomfortGastrointestinalUncommon
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• DiarrheaGastrointestinalUncommonLoose or frequent stools

Drug Interactions

• AntacidsLow
• NSAIDsModerateMay increase renal risk in susceptible patients

Population Constraints

• Pediatric patientsAgeRelative
• Patients with porcine product allergyAllergyAbsolute
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionApprovedApproved: Peptic ulcer disease, GastritisApproved in Italy and select European markets; not universally approved across all EU member states.
• United StatesUnapprovedNot approved by the FDA; not commercially available in the United States.
• United KingdomUnknownNot widely referenced in MHRA approved product lists; availability uncertain.

Approved in Italy and some other European and Asian markets for gastric and duodenal ulcer treatment. Not approved by the US FDA. Regulatory status varies widely by country.

Evidence & Sources

No sources recorded yet.